Apotex launches Apo-Semaglutide Injection™ in Canada as a generic equivalent of Ozempic®, expanding access to more affordable once-weekly semaglutide treatment options for adults with type 2 diabetes mellitus.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
Apotex has officially launched Apo-Semaglutide Injection™ in Canada, introducing a generic equivalent of Ozempic® for adults with type 2 diabetes mellitus. With initial inventory already shipping to wholesalers, the once-weekly semaglutide treatment is expected to reach pharmacy shelves across Canada within the coming weeks, expanding access to more affordable treatment options for patients and healthcare providers.
Health Canada approved Apo-Semaglutide Injection™ on May 1, 2026, clearing Apotex to launch its generic equivalent of Ozempic® for adults with type 2 diabetes in Canada.
The launch marks another major step in the growing availability of lower-cost GLP-1 therapies in Canada, where demand for semaglutide-based medicines continues to rise. Apo-Semaglutide Injection™ is indicated for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
To support a smooth transition from brand-name semaglutide, Apotex designed Apo-Semaglutide Injection™ with prefilled pen devices and instructions for use consistent with the reference product. The therapy is available in two approved formats, including a 2 mg pen delivering 0.25 mg or 0.5 mg doses and a 4 mg pen delivering 1 mg doses.
Martin Arès, President of Apotex Canada, said the launch reflects the company’s long-standing commitment to improving access to important medicines across the country.
“The launch of Apo-Semaglutide Injection reflects our Canadian roots and our dedication to making important treatment options more accessible to people across Canada,” said Arès. “With product now available, we are proud to offer a high-quality, affordable option that supports patients, prescribers, and contributes to a strong and reliable healthcare system for Canadians.”
Apo-Semaglutide Injection™ was developed in partnership with Orbicular Pharmaceutical Technologies and underwent Health Canada’s standard regulatory review for peptide medicines prior to approval.
The launch also builds on Apotex’s broader role in the Canadian healthcare system, where the company has spent more than five decades supplying affordable medicines aimed at improving treatment access while helping reduce healthcare costs nationwide.
Healthcare professionals are advised to consult the complete Product Monograph for full prescribing information, including warnings, precautions, adverse reactions, and patient monitoring recommendations.
Reference
Apotex launches Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.
